Title :

Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, ?-blockers or both in incident end-stage renal disease patients without cardiovascular disease: a propensity-matched longitudinal cohort study

Author(s) :

Ferreira, Joao Pedro [Auteur]
Centre Hospitalier Régional Universitaire de Nancy [CHRU Nancy]
Couchoud, Cecile [Auteur]
Agence de la biomédecine [Saint-Denis la Plaine]
Gregson, John [Auteur]
London School of Hygiene and Tropical Medicine [LSHTM]
Tiple, Aurelien [Auteur]
Service Néphrologie, Hémodialyses [CHU Clermont-Ferrand]
Glowacki, Francois [Auteur]
Impact de l'environnement chimique sur la santé humaine - ULR 4483 [IMPECS]
London, Gerard [Auteur]
Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy] [INI-CRCT]
Centre Hospitalier Manhès [Fleury-Mérogis]
Agarwal, Rajiv [Auteur]
Indiana University School of Medicine
Rossignol, Patrick [Auteur]
Centre Hospitalier Régional Universitaire de Nancy [CHRU Nancy]

Journal title :

Nephrology, dialysis, transplantation . official publication of the European Dialysis and Transplant Association - European Renal Association

Abbreviated title :

Nephrol. Dial. Transplant.

Volume number :

34

Pages :

1216–1222

Publisher :

Oxford Academic

Publication date :

2018-12-24

ISSN :

1460-2385

Keyword(s) :

mortality
neurohormonal blocking agents
end-stage renal disease

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Background End-stage renal disease (ESRD) patients even without known cardiovascular (CV) disease have high mortality rates. Whether neurohormonal blockade treatments improve outcomes in this population remains unknown. ...
Show more >Background End-stage renal disease (ESRD) patients even without known cardiovascular (CV) disease have high mortality rates. Whether neurohormonal blockade treatments improve outcomes in this population remains unknown. The aim of this study was to assess the effect of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARBs), β-blockers or both in all-cause mortality rates in incident ESRD patients without known CV disease starting renal replacement therapy (RRT) between 2009 and 2015 in the nationwide Réseau Epidémiologie et Information en Néphrologie registry. Methods Patients with known CV disease and those who started emergency RRT, stopped RRT or died within 6 months were excluded. Propensity score matching models were used. The main outcome was all-cause mortality. Results A total of 13 741 patients were included in this analysis. The median follow-up time was 24 months. When compared with matched controls without antihypertensive treatment, treatment with ACEi/ARBs, β-blockers and ACEi/ARBs + β-blockers was associated with an event-rate reduction per 100 person-years: ACEi/ARBs 7.6 [95% confidence interval (CI) 7.1–8.2] versus matched controls 9.5 (8.8–10.1) [HR 0.76 (95% CI 0.69–0.84)], β-blocker 7.1 (6.6–7.7) versus matched controls 9.5 (8.5–10.2) [HR 0.72 (0.65–0.80)] and ACEi/ARBs + β-blockers 5.8 (5.4–6.4) versus matched controls 7.8 (7.2–8.4) [HR 0.68 (0.61–0.77)]. Conclusions Neurohormonal blocking therapies were associated with death rate reduction in incident ESRD without CV disease. Whether these relationships are causal will require randomized controlled trials.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
Institut Pasteur de Lille
Université de Lille

Collections :

• IMPact de l'Environnement Chimique sur la Santé humaine (IMPECS) - ULR 4483

Submission date :

2022-02-02T10:24:05Z
2024-03-13T10:18:29Z